Kolmar BioTech（A215380）株式概要WOOJUNG BIO, Inc.は、非臨床試験代行サービスを提供しています。 詳細A215380 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性3/6配当金0/6リスク分析意味のある時価総額がありません ( ₩42B )すべてのリスクチェックを見るA215380 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW483,546 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA483,546 investors already sharing narrativesYour Fair Value₩Current Price₩2.53k68.5% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-12b48b2016201920222025202620282031Revenue ₩48.1bEarnings ₩6.1bAdvancedSet Fair ValueView all narrativesKolmar BioTech, Inc. 競合他社HLB bioStepLtdSymbol: KOSDAQ:A278650Market cap: ₩32.5bAligned GeneticsSymbol: KOSDAQ:A238120Market cap: ₩43.6bSLS BIOSymbol: KOSDAQ:A246250Market cap: ₩26.9bBiotoxtechSymbol: KOSDAQ:A086040Market cap: ₩34.2b価格と性能株価の高値、安値、推移の概要Kolmar BioTech過去の株価現在の株価₩2,525.0052週高値₩4,535.0052週安値₩1,554.00ベータ0.501ヶ月の変化11.97%3ヶ月変化-19.33%1年変化53.59%3年間の変化-2.51%5年間の変化-67.29%IPOからの変化-55.99%最新ニュースお知らせ • Mar 31WOOJUNG BIO, Inc. announced that it has received KRW 35 billion in funding from Kolmar Holdings Co.,Ltd.On March 30, 2026, WOOJUNG BIO, Inc. closed the transaction.お知らせ • Mar 17WOOJUNG BIO, Inc., Annual General Meeting, Mar 31, 2026WOOJUNG BIO, Inc., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 593-8, dongtangiheung-ro, gyeonggi-do, hwaseong South Koreaお知らせ • Mar 04WOOJUNG BIO, Inc. announced that it expects to receive KRW 35 billion in funding from Kolmar Holdings Co.,Ltd.WOOJUNG BIO, Inc. announced a private placement of 9th Unregistered Interest Unsecured Private Convertible Bonds of the company to raise gross proceeds of KRW 35,000,000,000 on March 3, 2026. The transaction includes investor participation of Kolmar Holdings Co.,Ltd. for bonds. The Bonds are 100% convertible into 15,053,763 common shares of the company at a conversion price value of KRW 2,325 and carry interest rate of 0% and maturity interest rate of 4%. The conversion billing period starts from March 31, 2027 to February 28, 2030.The transaction has been approved by the board of directors of the company. The Bonds have a maturity date of March 3, 2030. The transaction is expected to close on March 30, 2026. The transaction is subject to 1 year hold period.New Risk • Mar 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩4.5b free cash flow). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩51.0b market cap, or US$34.5m).分析記事 • Jan 29WOOJUNG BIO, Inc. (KOSDAQ:215380) Shares Fly 34% But Investors Aren't Buying For GrowthWOOJUNG BIO, Inc. ( KOSDAQ:215380 ) shares have had a really impressive month, gaining 34% after a shaky period...分析記事 • Dec 27Health Check: How Prudently Does WOOJUNG BIO (KOSDAQ:215380) Use Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...最新情報をもっと見るRecent updatesお知らせ • Mar 31WOOJUNG BIO, Inc. announced that it has received KRW 35 billion in funding from Kolmar Holdings Co.,Ltd.On March 30, 2026, WOOJUNG BIO, Inc. closed the transaction.お知らせ • Mar 17WOOJUNG BIO, Inc., Annual General Meeting, Mar 31, 2026WOOJUNG BIO, Inc., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 593-8, dongtangiheung-ro, gyeonggi-do, hwaseong South Koreaお知らせ • Mar 04WOOJUNG BIO, Inc. announced that it expects to receive KRW 35 billion in funding from Kolmar Holdings Co.,Ltd.WOOJUNG BIO, Inc. announced a private placement of 9th Unregistered Interest Unsecured Private Convertible Bonds of the company to raise gross proceeds of KRW 35,000,000,000 on March 3, 2026. The transaction includes investor participation of Kolmar Holdings Co.,Ltd. for bonds. The Bonds are 100% convertible into 15,053,763 common shares of the company at a conversion price value of KRW 2,325 and carry interest rate of 0% and maturity interest rate of 4%. The conversion billing period starts from March 31, 2027 to February 28, 2030.The transaction has been approved by the board of directors of the company. The Bonds have a maturity date of March 3, 2030. The transaction is expected to close on March 30, 2026. The transaction is subject to 1 year hold period.New Risk • Mar 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩4.5b free cash flow). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩51.0b market cap, or US$34.5m).分析記事 • Jan 29WOOJUNG BIO, Inc. (KOSDAQ:215380) Shares Fly 34% But Investors Aren't Buying For GrowthWOOJUNG BIO, Inc. ( KOSDAQ:215380 ) shares have had a really impressive month, gaining 34% after a shaky period...分析記事 • Dec 27Health Check: How Prudently Does WOOJUNG BIO (KOSDAQ:215380) Use Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Nov 04WOOJUNG BIO, Inc.'s (KOSDAQ:215380) Share Price Is Matching Sentiment Around Its RevenuesWith a price-to-sales (or "P/S") ratio of 0.9x WOOJUNG BIO, Inc. ( KOSDAQ:215380 ) may be sending very bullish signals...New Risk • Aug 28New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩3.4b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩3.4b free cash flow). Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Market cap is less than US$100m (₩27.9b market cap, or US$20.1m).分析記事 • Aug 13Is WOOJUNG BIO (KOSDAQ:215380) A Risky Investment?KOSDAQ:A215380 1 Year Share Price vs Fair Value Explore WOOJUNG BIO's Fair Values from the Community and select yours...New Risk • Aug 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Market cap is less than US$100m (₩31.7b market cap, or US$23.0m).分析記事 • Jun 12WOOJUNG BIO, Inc.'s (KOSDAQ:215380) Price Is Right But Growth Is Lacking After Shares Rocket 26%WOOJUNG BIO, Inc. ( KOSDAQ:215380 ) shares have had a really impressive month, gaining 26% after a shaky period...New Risk • Mar 30New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 204% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (0.6x net interest cover). Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (23% increase in shares outstanding). Market cap is less than US$100m (₩24.9b market cap, or US$17.0m).お知らせ • Mar 14WOOJUNG BIO, Inc., Annual General Meeting, Mar 28, 2025WOOJUNG BIO, Inc., Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 593-8, dongtangiheung-ro, gyeonggi-do, hwaseong South KoreaNew Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Shareholders have been diluted in the past year (23% increase in shares outstanding). Market cap is less than US$100m (₩27.3b market cap, or US$19.0m).Valuation Update With 7 Day Price Move • Dec 16Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩1,719, the stock trades at a trailing P/E ratio of 9.4x. Average trailing P/E is 13x in the Life Sciences industry in South Korea. Total loss to shareholders of 75% over the past three years.分析記事 • Dec 09WOOJUNG BIO, Inc.'s (KOSDAQ:215380) 27% Dip In Price Shows Sentiment Is Matching RevenuesThe WOOJUNG BIO, Inc. ( KOSDAQ:215380 ) share price has fared very poorly over the last month, falling by a substantial...お知らせ • Nov 20WOOJUNG BIO, Inc. announced that it expects to receive KRW 2.0425 billion in funding from Shin Nippon Biomedical Laboratories, Ltd.WOOJUNG BIO, Inc. announced private placement of 950,000 common shares at a price of KRW 2,150 for gross proceeds of KRW 2,042,500,000 on November 20, 2024. The transaction includes participation from Shin Nippon Biomedical Laboratories, Ltd. The transaction has been approved by the board of directors of the company. The payment date of the transaction is December 5, 2024. The offering is subject to mandatory lockup for 1 year.分析記事 • Oct 14Why Investors Shouldn't Be Surprised By WOOJUNG BIO, Inc.'s (KOSDAQ:215380) 30% Share Price PlungeThe WOOJUNG BIO, Inc. ( KOSDAQ:215380 ) share price has softened a substantial 30% over the previous 30 days, handing...Valuation Update With 7 Day Price Move • Sep 10Investor sentiment deteriorates as stock falls 27%After last week's 27% share price decline to ₩1,917, the stock trades at a trailing P/E ratio of 25.8x. Average trailing P/E is 14x in the Life Sciences industry in South Korea. Total loss to shareholders of 70% over the past three years.Valuation Update With 7 Day Price Move • Aug 27Investor sentiment deteriorates as stock falls 25%After last week's 25% share price decline to ₩2,690, the stock trades at a trailing P/E ratio of 33.8x. Average trailing P/E is 15x in the Life Sciences industry in South Korea. Total loss to shareholders of 60% over the past three years.分析記事 • Aug 16WOOJUNG BIO, Inc.'s (KOSDAQ:215380) Shares Bounce 43% But Its Business Still Trails The IndustryWOOJUNG BIO, Inc. ( KOSDAQ:215380 ) shareholders have had their patience rewarded with a 43% share price jump in the...New Risk • Jul 25New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩248m free cash flow). Earnings have declined by 8.6% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Shareholders have been diluted in the past year (13% increase in shares outstanding). Market cap is less than US$100m (₩20.7b market cap, or US$15.0m).分析記事 • Jun 14Revenues Working Against WOOJUNG BIO, Inc.'s (KOSDAQ:215380) Share Price Following 26% DiveUnfortunately for some shareholders, the WOOJUNG BIO, Inc. ( KOSDAQ:215380 ) share price has dived 26% in the last...分析記事 • May 23Is WOOJUNG BIO (KOSDAQ:215380) Weighed On By Its Debt Load?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...New Risk • Feb 23New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩5.9b free cash flow). Earnings have declined by 9.4% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (5.3% increase in shares outstanding). Market cap is less than US$100m (₩26.2b market cap, or US$19.7m).New Risk • Sep 13New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩9.0b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩9.0b free cash flow). Earnings have declined by 9.4% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩31.8b market cap, or US$24.0m).New Risk • Jul 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 5.2% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Market cap is less than US$100m (₩36.7b market cap, or US$29.0m).お知らせ • Jun 01WOOJUNG BIO, Inc. announced that it has received KRW 5 billion in funding from Korea Investment Partners Co. Ltd.On May 31, 2023, WOOJUNG BIO, Inc. closed the transaction.お知らせ • May 27WOOJUNG BIO, Inc. announced that it expects to receive KRW 5 billion in funding from Korea Investment Partners Co. Ltd.WOOJUNG BIO, Inc. announced a private placement of series 8th unregistered private convertible bond for gross proceeds of KRW 5,000,000,000 on May 25, 2023. The transaction will involve participation from new investor Korea Investment Re-Up II Fund, a fund managed by Korea Investment Partners Co. Ltd. The transaction has been approved by the board of directors. The bonds to be issued will have a hold period of one year, post the closing. The bond will mature on May 31, 2027. The bonds will have surface interest rate of 0% and interest rate of maturity rate of 4%. The bonds are fully convertible at a price of KRW 3,143 per share into1,590,836 shares into 10.93% stake. The bonds conversion period starts from May 31, 2024 and ends on April 30, 2027. The transaction is expected to close on May 31, 2023.お知らせ • May 26WOOJUNG BIO, Inc. announced that it has received KRW 8.999979915 billion in funding from Mercury Asset Management Co., Ltd., Ryan Asset Management Co., Ltd., Timefolio Asset Management Co.,LtdOn May 25, 2022, WOOJUNG BIO, Inc. closed the transaction.お知らせ • Aug 28WOOJUNG BIO, Inc. announced that it has received KRW 5 billion in fundingOn August 27, 2021, WOOJUNG BIO, Inc. (KOSDAQ:A215380) closed the transaction.Is New 90 Day High Low • Feb 18New 90-day low: ₩7,110The company is down 41% from its price of ₩12,100 on 20 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 2.0% over the same period.Is New 90 Day High Low • Jan 29New 90-day low: ₩7,400The company is down 3.0% from its price of ₩7,620 on 30 October 2020. The South Korean market is up 33% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 23% over the same period.Valuation Update With 7 Day Price Move • Dec 01Market bids up stock over the past weekAfter last week's 20% share price gain to ₩13,100, the stock is trading at a trailing P/E ratio of 50x, up from the previous P/E ratio of 41.6x. This compares to an average P/E of 80x in the Life Sciences industry in South Korea. Total returns to shareholders over the past three years are 161%.Is New 90 Day High Low • Dec 01New 90-day high: ₩13,100The company is up 8.0% from its price of ₩12,150 on 02 September 2020. The South Korean market is up 10.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is up 2.0% over the same period.Valuation Update With 7 Day Price Move • Nov 19Market bids up stock over the past weekAfter last week's 51% share price gain to ₩11,600, the stock is trading at a trailing P/E ratio of 44.3x, up from the previous P/E ratio of 29.3x. This compares to an average P/E of 78x in the Life Sciences industry in South Korea. Total returns to shareholders over the past three years are 116%.Valuation Update With 7 Day Price Move • Nov 16Market bids up stock over the past weekAfter last week's 17% share price gain to ₩9,610, the stock is trading at a trailing P/E ratio of 36.7x, up from the previous P/E ratio of 31.2x. This compares to an average P/E of 77x in the Life Sciences industry in South Korea. Total returns to shareholders over the past three years are 93%.Is New 90 Day High Low • Oct 26New 90-day low: ₩7,590The company is down 10.0% from its price of ₩8,390 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is down 12% over the same period.お知らせ • Sep 19Chun Byung Nyun acquired an additional 6.4% stake in WOOJUNG BIO, Inc. (KOSDAQ:A215380) for KRW 4.4 billion.Chun Byung Nyun acquired an additional 6.4% stake in WOOJUNG BIO, Inc. (KOSDAQ:A215380) for KRW 4.4 billion on August 28, 2020. Chun Byung Nyun acquired 772,831 shares at KRW 5,661 per share by exercise of call option rights. Chun Byung Nyun completed the acquisition of an additional 6.4% stake in WOOJUNG BIO, Inc. (KOSDAQ:A215380) on August 28, 2020.お知らせ • Aug 17+ 1 more updateWOOJUNG BIO, Inc. announced that it expects to receive KRW 5.00000397 billion in fundingWOOJUNG BIO, Inc. (KOSDAQ:A215380) announced a private placement of 651,891 registered convertible preferred stock at a price of KRW 7,670 per share for gross proceeds of KRW 5,000,003,970 on July 31, 2020. The transaction will include participation from ST-Details 2020-3 Bio New Technology Association. The shares have a face value of KRW 500 per share. The shares have a conversion price of KRW 7,670 per share. The conversion period starts from August 14, 2021 and ends on August 14, 2025. The shares are issued at a discount of 10%. The transaction has been approved by the company's board of directors. The company expects to close the transaction on August 14, 2020.お知らせ • Jul 31ByungNyun Chun, Chief Executive Officer of WOOJUNG BIO, Inc., acquired an additional stake in WOOJUNG BIO, Inc. (KOSDAQ:A215380) for KRW 2 billion.ByungNyun Chun, Chief Executive Officer of WOOJUNG BIO, Inc., acquired an additional stake in WOOJUNG BIO, Inc. (KOSDAQ:A215380) for KRW 2 billion on July 22, 2020. Under the terms, ByungNyun acquired 353,294 shares of WOOJUNG at KRW 5,661 per share. On completion, ByungNyun holds 41.75% stake in WOOJUNG. ByungNyun Chun is financing this transaction by borrowing funds from HYUNDAI MOTOR SECURITIES CO.,LTD. and Hana Bank ByungNyun Chun, Chief Executive Officer of WOOJUNG BIO, Inc., completed the acquisition of an additional stake in WOOJUNG BIO, Inc. (KOSDAQ:A215380) on July 22, 2020.株主還元A215380KR Life SciencesKR 市場7D8.1%7.0%-2.3%1Y53.6%-13.1%97.1%株主還元を見る業界別リターン: A215380過去 1 年間で-13.1 % の収益を上げたKR Life Sciences業界を上回りました。リターン対市場: A215380は、過去 1 年間で97.1 % のリターンを上げたKR市場を下回りました。価格変動Is A215380's price volatile compared to industry and market?A215380 volatilityA215380 Average Weekly Movement7.5%Life Sciences Industry Average Movement12.0%Market Average Movement9.5%10% most volatile stocks in KR Market17.1%10% least volatile stocks in KR Market5.0%安定した株価: A215380 、 KR市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: A215380の 週次ボラティリティ ( 8% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1989n/aByungSeok Moonkolmarbiotech.comは、非臨床研究機関サービスを提供している。同社は1989年に設立され、韓国の華城市に拠点を置く。もっと見るKolmar BioTech, Inc. 基礎のまとめKolmar BioTech の収益と売上を時価総額と比較するとどうか。A215380 基礎統計学時価総額₩42.49b収益（TTM）-₩3.68b売上高(TTM)₩40.30b1.1xP/Sレシオ-11.6xPER（株価収益率A215380 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計A215380 損益計算書（TTM）収益₩40.30b売上原価₩28.86b売上総利益₩11.44bその他の費用₩15.12b収益-₩3.68b直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-218.47グロス・マージン28.39%純利益率-9.12%有利子負債／自己資本比率226.6%A215380 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/25 20:53終値2026/07/24 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Kolmar BioTech, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Jae Hoon ShinHanwha Investment & Securities Co., Ltd.
お知らせ • Mar 31WOOJUNG BIO, Inc. announced that it has received KRW 35 billion in funding from Kolmar Holdings Co.,Ltd.On March 30, 2026, WOOJUNG BIO, Inc. closed the transaction.
お知らせ • Mar 17WOOJUNG BIO, Inc., Annual General Meeting, Mar 31, 2026WOOJUNG BIO, Inc., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 593-8, dongtangiheung-ro, gyeonggi-do, hwaseong South Korea
お知らせ • Mar 04WOOJUNG BIO, Inc. announced that it expects to receive KRW 35 billion in funding from Kolmar Holdings Co.,Ltd.WOOJUNG BIO, Inc. announced a private placement of 9th Unregistered Interest Unsecured Private Convertible Bonds of the company to raise gross proceeds of KRW 35,000,000,000 on March 3, 2026. The transaction includes investor participation of Kolmar Holdings Co.,Ltd. for bonds. The Bonds are 100% convertible into 15,053,763 common shares of the company at a conversion price value of KRW 2,325 and carry interest rate of 0% and maturity interest rate of 4%. The conversion billing period starts from March 31, 2027 to February 28, 2030.The transaction has been approved by the board of directors of the company. The Bonds have a maturity date of March 3, 2030. The transaction is expected to close on March 30, 2026. The transaction is subject to 1 year hold period.
New Risk • Mar 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩4.5b free cash flow). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩51.0b market cap, or US$34.5m).
分析記事 • Jan 29WOOJUNG BIO, Inc. (KOSDAQ:215380) Shares Fly 34% But Investors Aren't Buying For GrowthWOOJUNG BIO, Inc. ( KOSDAQ:215380 ) shares have had a really impressive month, gaining 34% after a shaky period...
分析記事 • Dec 27Health Check: How Prudently Does WOOJUNG BIO (KOSDAQ:215380) Use Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
お知らせ • Mar 31WOOJUNG BIO, Inc. announced that it has received KRW 35 billion in funding from Kolmar Holdings Co.,Ltd.On March 30, 2026, WOOJUNG BIO, Inc. closed the transaction.
お知らせ • Mar 17WOOJUNG BIO, Inc., Annual General Meeting, Mar 31, 2026WOOJUNG BIO, Inc., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 593-8, dongtangiheung-ro, gyeonggi-do, hwaseong South Korea
お知らせ • Mar 04WOOJUNG BIO, Inc. announced that it expects to receive KRW 35 billion in funding from Kolmar Holdings Co.,Ltd.WOOJUNG BIO, Inc. announced a private placement of 9th Unregistered Interest Unsecured Private Convertible Bonds of the company to raise gross proceeds of KRW 35,000,000,000 on March 3, 2026. The transaction includes investor participation of Kolmar Holdings Co.,Ltd. for bonds. The Bonds are 100% convertible into 15,053,763 common shares of the company at a conversion price value of KRW 2,325 and carry interest rate of 0% and maturity interest rate of 4%. The conversion billing period starts from March 31, 2027 to February 28, 2030.The transaction has been approved by the board of directors of the company. The Bonds have a maturity date of March 3, 2030. The transaction is expected to close on March 30, 2026. The transaction is subject to 1 year hold period.
New Risk • Mar 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩4.5b free cash flow). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩51.0b market cap, or US$34.5m).
分析記事 • Jan 29WOOJUNG BIO, Inc. (KOSDAQ:215380) Shares Fly 34% But Investors Aren't Buying For GrowthWOOJUNG BIO, Inc. ( KOSDAQ:215380 ) shares have had a really impressive month, gaining 34% after a shaky period...
分析記事 • Dec 27Health Check: How Prudently Does WOOJUNG BIO (KOSDAQ:215380) Use Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
分析記事 • Nov 04WOOJUNG BIO, Inc.'s (KOSDAQ:215380) Share Price Is Matching Sentiment Around Its RevenuesWith a price-to-sales (or "P/S") ratio of 0.9x WOOJUNG BIO, Inc. ( KOSDAQ:215380 ) may be sending very bullish signals...
New Risk • Aug 28New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩3.4b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩3.4b free cash flow). Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Market cap is less than US$100m (₩27.9b market cap, or US$20.1m).
分析記事 • Aug 13Is WOOJUNG BIO (KOSDAQ:215380) A Risky Investment?KOSDAQ:A215380 1 Year Share Price vs Fair Value Explore WOOJUNG BIO's Fair Values from the Community and select yours...
New Risk • Aug 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Market cap is less than US$100m (₩31.7b market cap, or US$23.0m).
分析記事 • Jun 12WOOJUNG BIO, Inc.'s (KOSDAQ:215380) Price Is Right But Growth Is Lacking After Shares Rocket 26%WOOJUNG BIO, Inc. ( KOSDAQ:215380 ) shares have had a really impressive month, gaining 26% after a shaky period...
New Risk • Mar 30New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 204% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (0.6x net interest cover). Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (23% increase in shares outstanding). Market cap is less than US$100m (₩24.9b market cap, or US$17.0m).
お知らせ • Mar 14WOOJUNG BIO, Inc., Annual General Meeting, Mar 28, 2025WOOJUNG BIO, Inc., Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 593-8, dongtangiheung-ro, gyeonggi-do, hwaseong South Korea
New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Shareholders have been diluted in the past year (23% increase in shares outstanding). Market cap is less than US$100m (₩27.3b market cap, or US$19.0m).
Valuation Update With 7 Day Price Move • Dec 16Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩1,719, the stock trades at a trailing P/E ratio of 9.4x. Average trailing P/E is 13x in the Life Sciences industry in South Korea. Total loss to shareholders of 75% over the past three years.
分析記事 • Dec 09WOOJUNG BIO, Inc.'s (KOSDAQ:215380) 27% Dip In Price Shows Sentiment Is Matching RevenuesThe WOOJUNG BIO, Inc. ( KOSDAQ:215380 ) share price has fared very poorly over the last month, falling by a substantial...
お知らせ • Nov 20WOOJUNG BIO, Inc. announced that it expects to receive KRW 2.0425 billion in funding from Shin Nippon Biomedical Laboratories, Ltd.WOOJUNG BIO, Inc. announced private placement of 950,000 common shares at a price of KRW 2,150 for gross proceeds of KRW 2,042,500,000 on November 20, 2024. The transaction includes participation from Shin Nippon Biomedical Laboratories, Ltd. The transaction has been approved by the board of directors of the company. The payment date of the transaction is December 5, 2024. The offering is subject to mandatory lockup for 1 year.
分析記事 • Oct 14Why Investors Shouldn't Be Surprised By WOOJUNG BIO, Inc.'s (KOSDAQ:215380) 30% Share Price PlungeThe WOOJUNG BIO, Inc. ( KOSDAQ:215380 ) share price has softened a substantial 30% over the previous 30 days, handing...
Valuation Update With 7 Day Price Move • Sep 10Investor sentiment deteriorates as stock falls 27%After last week's 27% share price decline to ₩1,917, the stock trades at a trailing P/E ratio of 25.8x. Average trailing P/E is 14x in the Life Sciences industry in South Korea. Total loss to shareholders of 70% over the past three years.
Valuation Update With 7 Day Price Move • Aug 27Investor sentiment deteriorates as stock falls 25%After last week's 25% share price decline to ₩2,690, the stock trades at a trailing P/E ratio of 33.8x. Average trailing P/E is 15x in the Life Sciences industry in South Korea. Total loss to shareholders of 60% over the past three years.
分析記事 • Aug 16WOOJUNG BIO, Inc.'s (KOSDAQ:215380) Shares Bounce 43% But Its Business Still Trails The IndustryWOOJUNG BIO, Inc. ( KOSDAQ:215380 ) shareholders have had their patience rewarded with a 43% share price jump in the...
New Risk • Jul 25New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩248m free cash flow). Earnings have declined by 8.6% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Shareholders have been diluted in the past year (13% increase in shares outstanding). Market cap is less than US$100m (₩20.7b market cap, or US$15.0m).
分析記事 • Jun 14Revenues Working Against WOOJUNG BIO, Inc.'s (KOSDAQ:215380) Share Price Following 26% DiveUnfortunately for some shareholders, the WOOJUNG BIO, Inc. ( KOSDAQ:215380 ) share price has dived 26% in the last...
分析記事 • May 23Is WOOJUNG BIO (KOSDAQ:215380) Weighed On By Its Debt Load?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
New Risk • Feb 23New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩5.9b free cash flow). Earnings have declined by 9.4% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (5.3% increase in shares outstanding). Market cap is less than US$100m (₩26.2b market cap, or US$19.7m).
New Risk • Sep 13New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩9.0b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩9.0b free cash flow). Earnings have declined by 9.4% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩31.8b market cap, or US$24.0m).
New Risk • Jul 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 5.2% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Market cap is less than US$100m (₩36.7b market cap, or US$29.0m).
お知らせ • Jun 01WOOJUNG BIO, Inc. announced that it has received KRW 5 billion in funding from Korea Investment Partners Co. Ltd.On May 31, 2023, WOOJUNG BIO, Inc. closed the transaction.
お知らせ • May 27WOOJUNG BIO, Inc. announced that it expects to receive KRW 5 billion in funding from Korea Investment Partners Co. Ltd.WOOJUNG BIO, Inc. announced a private placement of series 8th unregistered private convertible bond for gross proceeds of KRW 5,000,000,000 on May 25, 2023. The transaction will involve participation from new investor Korea Investment Re-Up II Fund, a fund managed by Korea Investment Partners Co. Ltd. The transaction has been approved by the board of directors. The bonds to be issued will have a hold period of one year, post the closing. The bond will mature on May 31, 2027. The bonds will have surface interest rate of 0% and interest rate of maturity rate of 4%. The bonds are fully convertible at a price of KRW 3,143 per share into1,590,836 shares into 10.93% stake. The bonds conversion period starts from May 31, 2024 and ends on April 30, 2027. The transaction is expected to close on May 31, 2023.
お知らせ • May 26WOOJUNG BIO, Inc. announced that it has received KRW 8.999979915 billion in funding from Mercury Asset Management Co., Ltd., Ryan Asset Management Co., Ltd., Timefolio Asset Management Co.,LtdOn May 25, 2022, WOOJUNG BIO, Inc. closed the transaction.
お知らせ • Aug 28WOOJUNG BIO, Inc. announced that it has received KRW 5 billion in fundingOn August 27, 2021, WOOJUNG BIO, Inc. (KOSDAQ:A215380) closed the transaction.
Is New 90 Day High Low • Feb 18New 90-day low: ₩7,110The company is down 41% from its price of ₩12,100 on 20 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 2.0% over the same period.
Is New 90 Day High Low • Jan 29New 90-day low: ₩7,400The company is down 3.0% from its price of ₩7,620 on 30 October 2020. The South Korean market is up 33% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 23% over the same period.
Valuation Update With 7 Day Price Move • Dec 01Market bids up stock over the past weekAfter last week's 20% share price gain to ₩13,100, the stock is trading at a trailing P/E ratio of 50x, up from the previous P/E ratio of 41.6x. This compares to an average P/E of 80x in the Life Sciences industry in South Korea. Total returns to shareholders over the past three years are 161%.
Is New 90 Day High Low • Dec 01New 90-day high: ₩13,100The company is up 8.0% from its price of ₩12,150 on 02 September 2020. The South Korean market is up 10.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is up 2.0% over the same period.
Valuation Update With 7 Day Price Move • Nov 19Market bids up stock over the past weekAfter last week's 51% share price gain to ₩11,600, the stock is trading at a trailing P/E ratio of 44.3x, up from the previous P/E ratio of 29.3x. This compares to an average P/E of 78x in the Life Sciences industry in South Korea. Total returns to shareholders over the past three years are 116%.
Valuation Update With 7 Day Price Move • Nov 16Market bids up stock over the past weekAfter last week's 17% share price gain to ₩9,610, the stock is trading at a trailing P/E ratio of 36.7x, up from the previous P/E ratio of 31.2x. This compares to an average P/E of 77x in the Life Sciences industry in South Korea. Total returns to shareholders over the past three years are 93%.
Is New 90 Day High Low • Oct 26New 90-day low: ₩7,590The company is down 10.0% from its price of ₩8,390 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is down 12% over the same period.
お知らせ • Sep 19Chun Byung Nyun acquired an additional 6.4% stake in WOOJUNG BIO, Inc. (KOSDAQ:A215380) for KRW 4.4 billion.Chun Byung Nyun acquired an additional 6.4% stake in WOOJUNG BIO, Inc. (KOSDAQ:A215380) for KRW 4.4 billion on August 28, 2020. Chun Byung Nyun acquired 772,831 shares at KRW 5,661 per share by exercise of call option rights. Chun Byung Nyun completed the acquisition of an additional 6.4% stake in WOOJUNG BIO, Inc. (KOSDAQ:A215380) on August 28, 2020.
お知らせ • Aug 17+ 1 more updateWOOJUNG BIO, Inc. announced that it expects to receive KRW 5.00000397 billion in fundingWOOJUNG BIO, Inc. (KOSDAQ:A215380) announced a private placement of 651,891 registered convertible preferred stock at a price of KRW 7,670 per share for gross proceeds of KRW 5,000,003,970 on July 31, 2020. The transaction will include participation from ST-Details 2020-3 Bio New Technology Association. The shares have a face value of KRW 500 per share. The shares have a conversion price of KRW 7,670 per share. The conversion period starts from August 14, 2021 and ends on August 14, 2025. The shares are issued at a discount of 10%. The transaction has been approved by the company's board of directors. The company expects to close the transaction on August 14, 2020.
お知らせ • Jul 31ByungNyun Chun, Chief Executive Officer of WOOJUNG BIO, Inc., acquired an additional stake in WOOJUNG BIO, Inc. (KOSDAQ:A215380) for KRW 2 billion.ByungNyun Chun, Chief Executive Officer of WOOJUNG BIO, Inc., acquired an additional stake in WOOJUNG BIO, Inc. (KOSDAQ:A215380) for KRW 2 billion on July 22, 2020. Under the terms, ByungNyun acquired 353,294 shares of WOOJUNG at KRW 5,661 per share. On completion, ByungNyun holds 41.75% stake in WOOJUNG. ByungNyun Chun is financing this transaction by borrowing funds from HYUNDAI MOTOR SECURITIES CO.,LTD. and Hana Bank ByungNyun Chun, Chief Executive Officer of WOOJUNG BIO, Inc., completed the acquisition of an additional stake in WOOJUNG BIO, Inc. (KOSDAQ:A215380) on July 22, 2020.
